Corcept Therapeutics | CORT - Selling And Administration Expenses

Stock Price
32.15
Daily Change
-0.24 -0.74%
Monthly
-18.87%
Yearly
-42.60%
Q1 Forecast
31.18

Corcept Therapeutics reported $114.74M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.73M 21.82M Dec/2025
Alaunos Therapeutics USD 585K 260K Sep/2025
ANI Pharmaceuticals USD 82.79M 6.13M Dec/2025
Ardelyx USD 83.61M 378K Sep/2025
Assertio Holdings USD 16.73M 1.66M Sep/2024
Aurora Cannabis CAD 41.79M 3.84M Sep/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Canopy Growth CAD 29.53M 999K Sep/2025
Corcept Therapeutics USD 114.74M 7.77M Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Esperion Therapeutics USD 39.98M 4.21M Sep/2024
J&J USD 6.75B 831M Dec/2025
Knight Therapeutics CAD 25.48M 119K Sep/2024
Lexicon Pharmaceuticals USD 39.19M 7.13M Jun/2024
Merck USD 2.85B 215M Dec/2025
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Novartis USD 3.31B 134M Sep/2025
Novartis USD 3.3B 137M Sep/2025
Omeros USD 11.32M 2.48M Sep/2024
Pacira USD 91.87M 70K Dec/2025
Pfizer USD 4.08B 894M Dec/2025
Supernus Pharmaceuticals USD 122.39M 57.29M Dec/2025
TG Therapeutics USD 50.73M 12.64M Dec/2025